nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Erythema facial—Hydroxyurea—brain cancer	0.0487	0.0593	CcSEcCtD
Brimonidine—Blindness—Lomustine—brain cancer	0.0327	0.0398	CcSEcCtD
Brimonidine—Conjunctival oedema—Carmustine—brain cancer	0.0259	0.0315	CcSEcCtD
Brimonidine—Hyperaemia—Carmustine—brain cancer	0.0238	0.029	CcSEcCtD
Brimonidine—Gastrointestinal symptom NOS—Hydroxyurea—brain cancer	0.0151	0.0184	CcSEcCtD
Brimonidine—Blepharitis—Hydroxyurea—brain cancer	0.0145	0.0176	CcSEcCtD
Brimonidine—Visual disturbance—Lomustine—brain cancer	0.0139	0.0169	CcSEcCtD
Brimonidine—Lethargy—Lomustine—brain cancer	0.0134	0.0163	CcSEcCtD
Brimonidine—Osteoarthritis—Lomustine—brain cancer	0.0131	0.016	CcSEcCtD
Brimonidine—Photophobia—Procarbazine—brain cancer	0.0108	0.0131	CcSEcCtD
Brimonidine—Coma—Procarbazine—brain cancer	0.0105	0.0128	CcSEcCtD
Brimonidine—Burning sensation—Carmustine—brain cancer	0.0104	0.0126	CcSEcCtD
Brimonidine—Scotoma—Carmustine—brain cancer	0.00947	0.0115	CcSEcCtD
Brimonidine—Scotoma—Temozolomide—brain cancer	0.00915	0.0111	CcSEcCtD
Brimonidine—Visual impairment—Lomustine—brain cancer	0.00876	0.0107	CcSEcCtD
Brimonidine—Lethargy—Procarbazine—brain cancer	0.00852	0.0104	CcSEcCtD
Brimonidine—Cyanosis—Etoposide—brain cancer	0.00786	0.00956	CcSEcCtD
Brimonidine—Infection—Carboplatin—brain cancer	0.00734	0.00893	CcSEcCtD
Brimonidine—Respiratory failure—Temozolomide—brain cancer	0.00708	0.00861	CcSEcCtD
Brimonidine—Coma—Carmustine—brain cancer	0.00657	0.008	CcSEcCtD
Brimonidine—Apnoea—Etoposide—brain cancer	0.00656	0.00798	CcSEcCtD
Brimonidine—Drowsiness—Procarbazine—brain cancer	0.00643	0.00782	CcSEcCtD
Brimonidine—Dry eye—Temozolomide—brain cancer	0.00642	0.00781	CcSEcCtD
Brimonidine—Infection—Lomustine—brain cancer	0.00642	0.00781	CcSEcCtD
Brimonidine—Pain—Carboplatin—brain cancer	0.00632	0.00768	CcSEcCtD
Brimonidine—Abnormal vision—Carmustine—brain cancer	0.00627	0.00763	CcSEcCtD
Brimonidine—Face oedema—Hydroxyurea—brain cancer	0.00624	0.00759	CcSEcCtD
Brimonidine—Abnormal vision—Temozolomide—brain cancer	0.00606	0.00737	CcSEcCtD
Brimonidine—Diabetes mellitus—Carmustine—brain cancer	0.006	0.0073	CcSEcCtD
Brimonidine—Swelling—Carmustine—brain cancer	0.00592	0.0072	CcSEcCtD
Brimonidine—Eye pain—Carmustine—brain cancer	0.00578	0.00704	CcSEcCtD
Brimonidine—Eye pain—Temozolomide—brain cancer	0.00559	0.0068	CcSEcCtD
Brimonidine—Nasal congestion—Temozolomide—brain cancer	0.00554	0.00674	CcSEcCtD
Brimonidine—Flushing—Procarbazine—brain cancer	0.00536	0.00652	CcSEcCtD
Brimonidine—Arrhythmia—Procarbazine—brain cancer	0.00516	0.00627	CcSEcCtD
Brimonidine—Face oedema—Carmustine—brain cancer	0.00504	0.00613	CcSEcCtD
Brimonidine—Drowsiness—Hydroxyurea—brain cancer	0.00498	0.00606	CcSEcCtD
Brimonidine—Face oedema—Temozolomide—brain cancer	0.00487	0.00593	CcSEcCtD
Brimonidine—Dry skin—Temozolomide—brain cancer	0.00463	0.00563	CcSEcCtD
Brimonidine—Swelling—Etoposide—brain cancer	0.00458	0.00557	CcSEcCtD
Brimonidine—Syncope—Procarbazine—brain cancer	0.00451	0.00548	CcSEcCtD
Brimonidine—Loss of consciousness—Procarbazine—brain cancer	0.00442	0.00537	CcSEcCtD
Brimonidine—Cough—Procarbazine—brain cancer	0.00439	0.00534	CcSEcCtD
Brimonidine—Hypertension—Procarbazine—brain cancer	0.00434	0.00528	CcSEcCtD
Brimonidine—Arthralgia—Procarbazine—brain cancer	0.00428	0.00521	CcSEcCtD
Brimonidine—Myalgia—Procarbazine—brain cancer	0.00428	0.00521	CcSEcCtD
Brimonidine—Anxiety—Procarbazine—brain cancer	0.00426	0.00519	CcSEcCtD
Brimonidine—Bronchitis—Temozolomide—brain cancer	0.00419	0.0051	CcSEcCtD
Brimonidine—Dry mouth—Procarbazine—brain cancer	0.00418	0.00509	CcSEcCtD
Brimonidine—Oedema—Procarbazine—brain cancer	0.0041	0.00499	CcSEcCtD
Brimonidine—Infection—Procarbazine—brain cancer	0.00408	0.00496	CcSEcCtD
Brimonidine—Angiopathy—Hydroxyurea—brain cancer	0.00405	0.00493	CcSEcCtD
Brimonidine—Shock—Procarbazine—brain cancer	0.00404	0.00491	CcSEcCtD
Brimonidine—Depression—Carmustine—brain cancer	0.00401	0.00488	CcSEcCtD
Brimonidine—Tachycardia—Procarbazine—brain cancer	0.004	0.00487	CcSEcCtD
Brimonidine—Erythema—Hydroxyurea—brain cancer	0.00389	0.00473	CcSEcCtD
Brimonidine—Depression—Temozolomide—brain cancer	0.00388	0.00472	CcSEcCtD
Brimonidine—Nausea—Lomustine—brain cancer	0.00384	0.00467	CcSEcCtD
Brimonidine—Hypotension—Procarbazine—brain cancer	0.00383	0.00466	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00374	0.00455	CcSEcCtD
Brimonidine—Insomnia—Procarbazine—brain cancer	0.00371	0.00451	CcSEcCtD
Brimonidine—Paraesthesia—Procarbazine—brain cancer	0.00368	0.00448	CcSEcCtD
Brimonidine—Sinusitis—Temozolomide—brain cancer	0.00365	0.00444	CcSEcCtD
Brimonidine—Somnolence—Procarbazine—brain cancer	0.00365	0.00444	CcSEcCtD
Brimonidine—Fatigue—Procarbazine—brain cancer	0.00354	0.0043	CcSEcCtD
Brimonidine—Pain—Procarbazine—brain cancer	0.00351	0.00427	CcSEcCtD
Brimonidine—Visual impairment—Carmustine—brain cancer	0.00348	0.00423	CcSEcCtD
Brimonidine—Pharyngitis—Temozolomide—brain cancer	0.00346	0.00421	CcSEcCtD
Brimonidine—Eye disorder—Carmustine—brain cancer	0.00338	0.00411	CcSEcCtD
Brimonidine—Visual impairment—Temozolomide—brain cancer	0.00336	0.00409	CcSEcCtD
Brimonidine—Flushing—Carmustine—brain cancer	0.00335	0.00408	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.00329	0.004	CcSEcCtD
Brimonidine—Discomfort—Hydroxyurea—brain cancer	0.00327	0.00398	CcSEcCtD
Brimonidine—Eye disorder—Temozolomide—brain cancer	0.00326	0.00397	CcSEcCtD
Brimonidine—Cardiac disorder—Temozolomide—brain cancer	0.00324	0.00394	CcSEcCtD
Brimonidine—Flushing—Temozolomide—brain cancer	0.00324	0.00394	CcSEcCtD
Brimonidine—Arrhythmia—Carmustine—brain cancer	0.00323	0.00393	CcSEcCtD
Brimonidine—Oedema—Hydroxyurea—brain cancer	0.00317	0.00386	CcSEcCtD
Brimonidine—Angiopathy—Temozolomide—brain cancer	0.00317	0.00385	CcSEcCtD
Brimonidine—Mental disorder—Carmustine—brain cancer	0.00316	0.00385	CcSEcCtD
Brimonidine—Infection—Hydroxyurea—brain cancer	0.00315	0.00384	CcSEcCtD
Brimonidine—Immune system disorder—Temozolomide—brain cancer	0.00315	0.00384	CcSEcCtD
Brimonidine—Mediastinal disorder—Temozolomide—brain cancer	0.00315	0.00383	CcSEcCtD
Brimonidine—Erythema—Carmustine—brain cancer	0.00314	0.00383	CcSEcCtD
Brimonidine—Nervous system disorder—Hydroxyurea—brain cancer	0.00311	0.00379	CcSEcCtD
Brimonidine—Skin disorder—Hydroxyurea—brain cancer	0.00308	0.00375	CcSEcCtD
Brimonidine—Mental disorder—Temozolomide—brain cancer	0.00306	0.00372	CcSEcCtD
Brimonidine—Erythema—Temozolomide—brain cancer	0.00304	0.0037	CcSEcCtD
Brimonidine—Hypersensitivity—Procarbazine—brain cancer	0.00302	0.00368	CcSEcCtD
Brimonidine—Dysgeusia—Temozolomide—brain cancer	0.00298	0.00362	CcSEcCtD
Brimonidine—Vision blurred—Carmustine—brain cancer	0.00296	0.00361	CcSEcCtD
Brimonidine—Asthenia—Procarbazine—brain cancer	0.00294	0.00358	CcSEcCtD
Brimonidine—Pruritus—Procarbazine—brain cancer	0.0029	0.00353	CcSEcCtD
Brimonidine—Vision blurred—Temozolomide—brain cancer	0.00286	0.00348	CcSEcCtD
Brimonidine—Dyspnoea—Hydroxyurea—brain cancer	0.00283	0.00344	CcSEcCtD
Brimonidine—Somnolence—Hydroxyurea—brain cancer	0.00282	0.00343	CcSEcCtD
Brimonidine—Dyspepsia—Hydroxyurea—brain cancer	0.00279	0.0034	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00274	0.00333	CcSEcCtD
Brimonidine—Fatigue—Hydroxyurea—brain cancer	0.00274	0.00333	CcSEcCtD
Brimonidine—Hypertension—Carmustine—brain cancer	0.00271	0.0033	CcSEcCtD
Brimonidine—Pain—Hydroxyurea—brain cancer	0.00271	0.0033	CcSEcCtD
Brimonidine—Dizziness—Procarbazine—brain cancer	0.00271	0.0033	CcSEcCtD
Brimonidine—Palpitations—Temozolomide—brain cancer	0.00269	0.00327	CcSEcCtD
Brimonidine—Chest pain—Carmustine—brain cancer	0.00268	0.00326	CcSEcCtD
Brimonidine—Myalgia—Carmustine—brain cancer	0.00268	0.00326	CcSEcCtD
Brimonidine—Anxiety—Carmustine—brain cancer	0.00267	0.00325	CcSEcCtD
Brimonidine—Cough—Temozolomide—brain cancer	0.00265	0.00323	CcSEcCtD
Brimonidine—Hypertension—Temozolomide—brain cancer	0.00262	0.00319	CcSEcCtD
Brimonidine—Eye disorder—Etoposide—brain cancer	0.00261	0.00318	CcSEcCtD
Brimonidine—Flushing—Etoposide—brain cancer	0.00259	0.00315	CcSEcCtD
Brimonidine—Cardiac disorder—Etoposide—brain cancer	0.00259	0.00315	CcSEcCtD
Brimonidine—Myalgia—Temozolomide—brain cancer	0.00259	0.00315	CcSEcCtD
Brimonidine—Arthralgia—Temozolomide—brain cancer	0.00259	0.00315	CcSEcCtD
Brimonidine—Rash—Procarbazine—brain cancer	0.00259	0.00315	CcSEcCtD
Brimonidine—Dermatitis—Procarbazine—brain cancer	0.00258	0.00314	CcSEcCtD
Brimonidine—Anxiety—Temozolomide—brain cancer	0.00258	0.00314	CcSEcCtD
Brimonidine—Headache—Procarbazine—brain cancer	0.00257	0.00313	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00257	0.00313	CcSEcCtD
Brimonidine—Oedema—Carmustine—brain cancer	0.00257	0.00312	CcSEcCtD
Brimonidine—Discomfort—Temozolomide—brain cancer	0.00256	0.00311	CcSEcCtD
Brimonidine—Infection—Carmustine—brain cancer	0.00255	0.0031	CcSEcCtD
Brimonidine—Angiopathy—Etoposide—brain cancer	0.00253	0.00308	CcSEcCtD
Brimonidine—Dry mouth—Temozolomide—brain cancer	0.00253	0.00308	CcSEcCtD
Brimonidine—Immune system disorder—Etoposide—brain cancer	0.00252	0.00307	CcSEcCtD
Brimonidine—Mediastinal disorder—Etoposide—brain cancer	0.00252	0.00306	CcSEcCtD
Brimonidine—Tachycardia—Carmustine—brain cancer	0.0025	0.00305	CcSEcCtD
Brimonidine—Oedema—Temozolomide—brain cancer	0.00248	0.00302	CcSEcCtD
Brimonidine—Infection—Temozolomide—brain cancer	0.00246	0.003	CcSEcCtD
Brimonidine—Nausea—Procarbazine—brain cancer	0.00244	0.00296	CcSEcCtD
Brimonidine—Nervous system disorder—Temozolomide—brain cancer	0.00243	0.00296	CcSEcCtD
Brimonidine—Skin disorder—Temozolomide—brain cancer	0.00241	0.00293	CcSEcCtD
Brimonidine—Hypotension—Carmustine—brain cancer	0.0024	0.00292	CcSEcCtD
Brimonidine—Dysgeusia—Etoposide—brain cancer	0.00238	0.0029	CcSEcCtD
Brimonidine—Hypersensitivity—Hydroxyurea—brain cancer	0.00234	0.00285	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Carmustine—brain cancer	0.00234	0.00284	CcSEcCtD
Brimonidine—Insomnia—Carmustine—brain cancer	0.00232	0.00282	CcSEcCtD
Brimonidine—Paraesthesia—Carmustine—brain cancer	0.0023	0.0028	CcSEcCtD
Brimonidine—Dyspnoea—Carmustine—brain cancer	0.00229	0.00278	CcSEcCtD
Brimonidine—Somnolence—Carmustine—brain cancer	0.00228	0.00278	CcSEcCtD
Brimonidine—Asthenia—Hydroxyurea—brain cancer	0.00228	0.00277	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Temozolomide—brain cancer	0.00226	0.00275	CcSEcCtD
Brimonidine—Insomnia—Temozolomide—brain cancer	0.00224	0.00273	CcSEcCtD
Brimonidine—Paraesthesia—Temozolomide—brain cancer	0.00223	0.00271	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Carmustine—brain cancer	0.00222	0.0027	CcSEcCtD
Brimonidine—Dyspnoea—Temozolomide—brain cancer	0.00221	0.00269	CcSEcCtD
Brimonidine—Somnolence—Temozolomide—brain cancer	0.0022	0.00268	CcSEcCtD
Brimonidine—Pain—Carmustine—brain cancer	0.00219	0.00267	CcSEcCtD
Brimonidine—Dyspepsia—Temozolomide—brain cancer	0.00218	0.00266	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Temozolomide—brain cancer	0.00214	0.0026	CcSEcCtD
Brimonidine—Fatigue—Temozolomide—brain cancer	0.00214	0.0026	CcSEcCtD
Brimonidine—Loss of consciousness—Etoposide—brain cancer	0.00214	0.0026	CcSEcCtD
Brimonidine—Cough—Etoposide—brain cancer	0.00212	0.00258	CcSEcCtD
Brimonidine—Pain—Temozolomide—brain cancer	0.00212	0.00258	CcSEcCtD
Brimonidine—Hypertension—Etoposide—brain cancer	0.0021	0.00255	CcSEcCtD
Brimonidine—Dizziness—Hydroxyurea—brain cancer	0.0021	0.00255	CcSEcCtD
Brimonidine—Chest pain—Etoposide—brain cancer	0.00207	0.00252	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.00206	0.0025	CcSEcCtD
Brimonidine—Discomfort—Etoposide—brain cancer	0.00205	0.00249	CcSEcCtD
Brimonidine—Rash—Hydroxyurea—brain cancer	0.002	0.00243	CcSEcCtD
Brimonidine—Dermatitis—Hydroxyurea—brain cancer	0.002	0.00243	CcSEcCtD
Brimonidine—Headache—Hydroxyurea—brain cancer	0.00199	0.00242	CcSEcCtD
Brimonidine—Infection—Etoposide—brain cancer	0.00197	0.0024	CcSEcCtD
Brimonidine—Tachycardia—Etoposide—brain cancer	0.00194	0.00236	CcSEcCtD
Brimonidine—Skin disorder—Etoposide—brain cancer	0.00193	0.00234	CcSEcCtD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—MPL—brain cancer	0.0019	0.0107	CbGpPWpGaD
Brimonidine—Hypersensitivity—Carmustine—brain cancer	0.00189	0.0023	CcSEcCtD
Brimonidine—Nausea—Hydroxyurea—brain cancer	0.00189	0.00229	CcSEcCtD
Brimonidine—Hypotension—Etoposide—brain cancer	0.00185	0.00226	CcSEcCtD
Brimonidine—Asthenia—Carmustine—brain cancer	0.00184	0.00224	CcSEcCtD
Brimonidine—Hypersensitivity—Temozolomide—brain cancer	0.00183	0.00222	CcSEcCtD
Brimonidine—Paraesthesia—Etoposide—brain cancer	0.00178	0.00217	CcSEcCtD
Brimonidine—Asthenia—Temozolomide—brain cancer	0.00178	0.00216	CcSEcCtD
Brimonidine—Dyspnoea—Etoposide—brain cancer	0.00177	0.00215	CcSEcCtD
Brimonidine—Somnolence—Etoposide—brain cancer	0.00176	0.00215	CcSEcCtD
Brimonidine—Pruritus—Temozolomide—brain cancer	0.00175	0.00213	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Etoposide—brain cancer	0.00171	0.00208	CcSEcCtD
Brimonidine—Fatigue—Etoposide—brain cancer	0.00171	0.00208	CcSEcCtD
Brimonidine—Dizziness—Carmustine—brain cancer	0.0017	0.00206	CcSEcCtD
Brimonidine—Pain—Etoposide—brain cancer	0.0017	0.00206	CcSEcCtD
Brimonidine—Dizziness—Temozolomide—brain cancer	0.00164	0.002	CcSEcCtD
Brimonidine—Rash—Carmustine—brain cancer	0.00162	0.00197	CcSEcCtD
Brimonidine—Dermatitis—Carmustine—brain cancer	0.00162	0.00197	CcSEcCtD
Brimonidine—Headache—Carmustine—brain cancer	0.00161	0.00196	CcSEcCtD
Brimonidine—Rash—Temozolomide—brain cancer	0.00156	0.0019	CcSEcCtD
Brimonidine—Dermatitis—Temozolomide—brain cancer	0.00156	0.0019	CcSEcCtD
Brimonidine—Headache—Temozolomide—brain cancer	0.00155	0.00189	CcSEcCtD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—MPL—brain cancer	0.00154	0.00865	CbGpPWpGaD
Brimonidine—Nausea—Carmustine—brain cancer	0.00152	0.00185	CcSEcCtD
Brimonidine—Nausea—Temozolomide—brain cancer	0.00147	0.00179	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—brain cancer	0.00146	0.00178	CcSEcCtD
Brimonidine—Asthenia—Etoposide—brain cancer	0.00142	0.00173	CcSEcCtD
Brimonidine—Pruritus—Etoposide—brain cancer	0.0014	0.00171	CcSEcCtD
Brimonidine—Dizziness—Etoposide—brain cancer	0.00131	0.0016	CcSEcCtD
Brimonidine—AOX1—Disease—DTX2—brain cancer	0.00128	0.00717	CbGpPWpGaD
Brimonidine—Rash—Etoposide—brain cancer	0.00125	0.00152	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—brain cancer	0.00125	0.00152	CcSEcCtD
Brimonidine—Headache—Etoposide—brain cancer	0.00124	0.00151	CcSEcCtD
Brimonidine—Nausea—Etoposide—brain cancer	0.00118	0.00143	CcSEcCtD
Brimonidine—ADRA2B—Hemostasis—MPL—brain cancer	0.00105	0.00588	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—PTCH2—brain cancer	0.00104	0.00586	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—S100A10—brain cancer	0.001	0.00563	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—MPL—brain cancer	0.000977	0.00549	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—PTCH2—brain cancer	0.000974	0.00547	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—S100A10—brain cancer	0.000937	0.00526	CbGpPWpGaD
Brimonidine—AOX1—Disease—HES5—brain cancer	0.000936	0.00526	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—OR14C36—brain cancer	0.000914	0.00514	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—OR4C12—brain cancer	0.000914	0.00514	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—TRPC6—brain cancer	0.000898	0.00505	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—OR4C12—brain cancer	0.000854	0.0048	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—OR14C36—brain cancer	0.000854	0.0048	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—TRPC6—brain cancer	0.000839	0.00472	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—OR4C12—brain cancer	0.00083	0.00467	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—OR14C36—brain cancer	0.00083	0.00467	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—MPL—brain cancer	0.000794	0.00446	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—PTCH2—brain cancer	0.000791	0.00444	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—OR4C12—brain cancer	0.000776	0.00436	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—OR14C36—brain cancer	0.000776	0.00436	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—S100A10—brain cancer	0.000761	0.00428	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—CYP2C9—brain cancer	0.000722	0.00405	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—BSG—brain cancer	0.000707	0.00397	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—OR14C36—brain cancer	0.000694	0.0039	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—OR4C12—brain cancer	0.000694	0.0039	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—TRPC6—brain cancer	0.000682	0.00383	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—VAV1—brain cancer	0.000673	0.00378	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—BSG—brain cancer	0.00066	0.00371	CbGpPWpGaD
Brimonidine—AOX1—Disease—IDH1—brain cancer	0.00063	0.00354	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—OR4C12—brain cancer	0.00063	0.00354	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—OR14C36—brain cancer	0.00063	0.00354	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—VAV1—brain cancer	0.000629	0.00353	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—BSG—brain cancer	0.000614	0.00345	CbGpPWpGaD
Brimonidine—AOX1—Disease—HEY1—brain cancer	0.000597	0.00336	CbGpPWpGaD
Brimonidine—AOX1—Disease—DLL1—brain cancer	0.000586	0.00329	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—SHH—brain cancer	0.000537	0.00302	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—BSG—brain cancer	0.000536	0.00301	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PTCH2—brain cancer	0.000535	0.00301	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—IDH1—brain cancer	0.000528	0.00296	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—VAV1—brain cancer	0.000511	0.00287	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—PTCH1—brain cancer	0.000509	0.00286	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—SMO—brain cancer	0.000509	0.00286	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—SHH—brain cancer	0.000502	0.00282	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PTCH2—brain cancer	0.0005	0.00281	CbGpPWpGaD
Brimonidine—AOX1—Disease—ENO2—brain cancer	0.000498	0.0028	CbGpPWpGaD
Brimonidine—AOX1—Disease—SHH—brain cancer	0.000498	0.0028	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—OR14C36—brain cancer	0.00049	0.00276	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—OR4C12—brain cancer	0.00049	0.00276	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—PTCH1—brain cancer	0.000476	0.00267	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—SMO—brain cancer	0.000476	0.00267	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TRPC6—brain cancer	0.000463	0.0026	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ABR—brain cancer	0.000462	0.0026	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—OR4C12—brain cancer	0.000458	0.00257	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—OR14C36—brain cancer	0.000458	0.00257	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TRPC6—brain cancer	0.000433	0.00243	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—ABR—brain cancer	0.000432	0.00243	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	0.000427	0.0024	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ABR—brain cancer	0.00042	0.00236	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ENO2—brain cancer	0.000417	0.00234	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DTX2—brain cancer	0.000417	0.00234	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—SHH—brain cancer	0.000407	0.00229	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PTCH2—brain cancer	0.000406	0.00228	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	0.000399	0.00224	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—ABR—brain cancer	0.000392	0.0022	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DTX2—brain cancer	0.00039	0.00219	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—SMO—brain cancer	0.000386	0.00217	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—PTCH1—brain cancer	0.000386	0.00217	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—OR4C12—brain cancer	0.000372	0.00209	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—OR14C36—brain cancer	0.000372	0.00209	CbGpPWpGaD
Brimonidine—AOX1—Disease—VAV1—brain cancer	0.00036	0.00202	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TRPC6—brain cancer	0.000351	0.00197	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—ABR—brain cancer	0.000351	0.00197	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VAV1—brain cancer	0.000347	0.00195	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	0.000324	0.00182	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VAV1—brain cancer	0.000324	0.00182	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ABR—brain cancer	0.000319	0.00179	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DTX2—brain cancer	0.000316	0.00178	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTCH2—brain cancer	0.000316	0.00178	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP2C9—brain cancer	0.000315	0.00177	CbGpPWpGaD
Brimonidine—AOX1—Disease—HES1—brain cancer	0.000309	0.00174	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HES5—brain cancer	0.000306	0.00172	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—IL2—brain cancer	0.000301	0.00169	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STRADA—brain cancer	0.000297	0.00167	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTCH2—brain cancer	0.000295	0.00166	CbGpPWpGaD
Brimonidine—AOX1—Disease—PDGFRA—brain cancer	0.000295	0.00166	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—TRPC6—brain cancer	0.000293	0.00164	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HES5—brain cancer	0.000286	0.00161	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—IL2—brain cancer	0.000281	0.00158	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STRADA—brain cancer	0.000278	0.00156	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—SHH—brain cancer	0.000276	0.00155	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—TRPC6—brain cancer	0.000273	0.00154	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—BSG—brain cancer	0.000268	0.0015	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—TRPC6—brain cancer	0.000266	0.00149	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VAV1—brain cancer	0.000263	0.00148	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PTCH1—brain cancer	0.000261	0.00147	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—SMO—brain cancer	0.000261	0.00147	CbGpPWpGaD
Brimonidine—AOX1—Disease—IRS2—brain cancer	0.000259	0.00145	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—SHH—brain cancer	0.000257	0.00145	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—brain cancer	0.000256	0.00144	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP2C9—brain cancer	0.000256	0.00144	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—TRPC6—brain cancer	0.000248	0.0014	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ABR—brain cancer	0.000248	0.00139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PTCH1—brain cancer	0.000244	0.00137	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—SMO—brain cancer	0.000244	0.00137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTCH2—brain cancer	0.00024	0.00135	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GLI2—brain cancer	0.00024	0.00135	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—brain cancer	0.000239	0.00134	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HES5—brain cancer	0.000232	0.00131	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ABR—brain cancer	0.000232	0.0013	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—IDH1—brain cancer	0.00023	0.00129	CbGpPWpGaD
Brimonidine—AOX1—Disease—APC—brain cancer	0.000228	0.00128	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—IL2—brain cancer	0.000228	0.00128	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STRADA—brain cancer	0.000225	0.00127	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GLI1—brain cancer	0.000225	0.00127	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GLI2—brain cancer	0.000224	0.00126	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—TRPC6—brain cancer	0.000222	0.00125	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—PIK3CG—brain cancer	0.00022	0.00124	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—VAV1—brain cancer	0.000219	0.00123	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—BSG—brain cancer	0.000217	0.00122	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SUFU—brain cancer	0.000213	0.0012	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GLI1—brain cancer	0.00021	0.00118	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—SHH—brain cancer	0.000209	0.00118	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GFAP—brain cancer	0.000206	0.00116	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PIK3CG—brain cancer	0.000206	0.00116	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—VAV1—brain cancer	0.000205	0.00115	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—TRPC6—brain cancer	0.000202	0.00113	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SUFU—brain cancer	0.000199	0.00112	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—VAV1—brain cancer	0.000199	0.00112	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—SMO—brain cancer	0.000198	0.00111	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PTCH1—brain cancer	0.000198	0.00111	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HEY1—brain cancer	0.000195	0.0011	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—brain cancer	0.000194	0.00109	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GFAP—brain cancer	0.000192	0.00108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DLL1—brain cancer	0.000191	0.00108	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CG—brain cancer	0.000191	0.00108	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ABR—brain cancer	0.000188	0.00106	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—IDH1—brain cancer	0.000187	0.00105	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—VAV1—brain cancer	0.000186	0.00105	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HEY1—brain cancer	0.000182	0.00102	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ENO2—brain cancer	0.000182	0.00102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GLI2—brain cancer	0.000182	0.00102	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DLL1—brain cancer	0.000179	0.00101	CbGpPWpGaD
Brimonidine—AOX1—Disease—ERBB2—brain cancer	0.000177	0.000997	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GLI1—brain cancer	0.000171	0.00096	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CG—brain cancer	0.000167	0.000939	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—VAV1—brain cancer	0.000166	0.000935	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SHH—brain cancer	0.000163	0.000915	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SUFU—brain cancer	0.000162	0.00091	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TRPC6—brain cancer	0.000157	0.000882	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GFAP—brain cancer	0.000156	0.000878	CbGpPWpGaD
Brimonidine—AOX1—Disease—CTNNB1—brain cancer	0.000155	0.000872	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—IL2—brain cancer	0.000155	0.000871	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SMO—brain cancer	0.000154	0.000867	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTCH1—brain cancer	0.000154	0.000867	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SHH—brain cancer	0.000152	0.000855	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—VAV1—brain cancer	0.000151	0.000849	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HEY1—brain cancer	0.000148	0.000832	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ENO2—brain cancer	0.000148	0.00083	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TRPC6—brain cancer	0.000147	0.000824	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DLL1—brain cancer	0.000145	0.000816	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—IL2—brain cancer	0.000145	0.000814	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SMO—brain cancer	0.000144	0.00081	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTCH1—brain cancer	0.000144	0.00081	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CG—brain cancer	0.000139	0.000782	CbGpPWpGaD
Brimonidine—AOX1—Disease—STAT3—brain cancer	0.000135	0.00076	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VEGFA—brain cancer	0.000132	0.00074	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CG—brain cancer	0.00013	0.000731	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CG—brain cancer	0.000126	0.00071	CbGpPWpGaD
Brimonidine—AOX1—Disease—MYC—brain cancer	0.000126	0.000706	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SHH—brain cancer	0.000124	0.000694	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH2—brain cancer	0.000123	0.000693	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VEGFA—brain cancer	0.000123	0.000692	CbGpPWpGaD
Brimonidine—AOX1—Disease—EGFR—brain cancer	0.000123	0.000691	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TRPC6—brain cancer	0.000119	0.000669	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CG—brain cancer	0.000118	0.000664	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VAV1—brain cancer	0.000118	0.000661	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IL2—brain cancer	0.000118	0.000661	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SMO—brain cancer	0.000117	0.000658	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTCH1—brain cancer	0.000117	0.000658	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH2—brain cancer	0.000115	0.000648	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VAV1—brain cancer	0.00011	0.000617	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CG—brain cancer	0.000106	0.000594	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HES1—brain cancer	0.000101	0.000568	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFA—brain cancer	0.0001	0.000562	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TP53—brain cancer	9.96e-05	0.000559	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—IL2—brain cancer	9.8e-05	0.000551	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDGFRA—brain cancer	9.63e-05	0.000541	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CG—brain cancer	9.59e-05	0.000539	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HES1—brain cancer	9.45e-05	0.000531	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH2—brain cancer	9.36e-05	0.000526	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SPP1—brain cancer	9.35e-05	0.000525	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—brain cancer	9.3e-05	0.000523	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2—brain cancer	9.15e-05	0.000514	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFRA—brain cancer	9e-05	0.000506	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VAV1—brain cancer	8.93e-05	0.000502	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—brain cancer	8.9e-05	0.0005	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SPP1—brain cancer	8.74e-05	0.000491	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS2—brain cancer	8.46e-05	0.000475	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—brain cancer	8.34e-05	0.000469	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—brain cancer	8.31e-05	0.000467	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS2—brain cancer	7.9e-05	0.000444	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HES1—brain cancer	7.68e-05	0.000431	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—brain cancer	7.55e-05	0.000424	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APC—brain cancer	7.47e-05	0.00042	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—brain cancer	7.47e-05	0.00042	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—brain cancer	7.43e-05	0.000418	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFRA—brain cancer	7.31e-05	0.000411	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SPP1—brain cancer	7.1e-05	0.000399	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APC—brain cancer	6.98e-05	0.000392	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—brain cancer	6.98e-05	0.000392	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—brain cancer	6.8e-05	0.000382	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—brain cancer	6.78e-05	0.000381	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—brain cancer	6.75e-05	0.000379	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS2—brain cancer	6.42e-05	0.000361	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—brain cancer	6.36e-05	0.000357	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RELA—brain cancer	5.84e-05	0.000328	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB2—brain cancer	5.8e-05	0.000326	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—brain cancer	5.67e-05	0.000318	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APC—brain cancer	5.67e-05	0.000318	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RELA—brain cancer	5.45e-05	0.000306	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB2—brain cancer	5.42e-05	0.000304	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—brain cancer	5.26e-05	0.000295	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—brain cancer	5.16e-05	0.00029	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—brain cancer	5.12e-05	0.000288	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CTNNB1—brain cancer	5.07e-05	0.000285	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—brain cancer	4.91e-05	0.000276	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—brain cancer	4.79e-05	0.000269	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CTNNB1—brain cancer	4.74e-05	0.000266	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—brain cancer	4.47e-05	0.000251	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RELA—brain cancer	4.43e-05	0.000249	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—brain cancer	4.42e-05	0.000249	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB2—brain cancer	4.4e-05	0.000247	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—brain cancer	4.17e-05	0.000234	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—brain cancer	4.13e-05	0.000232	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—brain cancer	4.11e-05	0.000231	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—brain cancer	4.02e-05	0.000226	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—brain cancer	3.99e-05	0.000224	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—brain cancer	3.89e-05	0.000218	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CTNNB1—brain cancer	3.85e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—brain cancer	3.84e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—brain cancer	3.76e-05	0.000211	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—brain cancer	3.39e-05	0.00019	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—brain cancer	3.38e-05	0.00019	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—brain cancer	3.36e-05	0.000189	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—brain cancer	3.15e-05	0.000177	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—brain cancer	3.12e-05	0.000175	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—brain cancer	3.05e-05	0.000171	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—brain cancer	2.56e-05	0.000144	CbGpPWpGaD
